Showing results (201-210 of 1,988) with videos related to

Sort By:
Pageof 199
Prostate Cancer and Prostatic Diseases|February 3, 2005
Heterocyclic amines and genotype of N-acetyltransferases as risk factors for prostate cancerP M Rovito, P D Morse, K Spinek, et al.
Prostate Cancer and Prostatic Diseases|September 29, 2004
5alpha-Androstane-3alpha,17beta-diol activates pathway that resembles the epidermal growth factor responsive pathways in stimulating human prostate cancer LNCaP cell proliferationR A Zimmerman, I Dozmorov, E H Nunlist, et al.
Prostate Cancer and Prostatic Diseases|July 28, 2004
Management of recurrent disease after radical prostatectomyS R J Bott
Prostate Cancer and Prostatic Diseases|July 28, 2004
Postradical prostatectomy TRUS-guided anastomotic biopsy. Where do we stand today?T Anagnostou, K Doumas, M Remzi, et al.
Prostate Cancer and Prostatic Diseases|April 6, 2005
The relationship between the androgen receptor CAG repeat polymorphism length and the response to intermittent androgen suppression therapy for advanced prostate cancerL Klotz, A Correia, W Zhang
Prostate Cancer and Prostatic Diseases|May 18, 2005
Evaluation of a new, rapid, qualitative, one-step PSA Test for prostate cancer screening: the PSA RapidScreen testR Miano, G O Mele, S Germani, et al.
Prostate Cancer and Prostatic Diseases|May 18, 2005
Subtoxic concentration of doxorubicin enhances TRAIL-induced apoptosis in human prostate cancer cell line LNCaPJ Kang, J Bu, Y Hao, et al.
Prostate Cancer and Prostatic Diseases|February 16, 2005
Long-term outcome of detectable PSA levels after radical prostatectomyT E Ahlering, D W Skarecky
Prostate Cancer and Prostatic Diseases|February 16, 2005
Nerve-sparing radical retropubic prostatectomy: techniques and clinical considerationsP Gontero, R S Kirby
Prostate Cancer and Prostatic Diseases|February 9, 2005
The impact of age and comorbidity on survival outcomes and treatment patterns in prostate cancerW H Hall, A B Jani, J K Ryu, et al.
Pageof 199